Lexicon submits additional data for its diabetes drug to US FDA

Lexicon Pharmaceuticals

22/09/2025 21:10

Corrects headline and text to say Lexicon announced update on previous submission of additional data, and not that it submitted data

Sept 22 (Reuters) - Lexicon Pharmaceuticals LXRX.O said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, Zynquista, for patients with type 1 diabetes.

 (Reporting by Siddhi Mahatole in Bengaluru; Editing by Mohammed Safi Shamsi)

 ((siddhi.mahatole@thomsonreuters.com;))